Cambridge Enterprise Limited

University of Glasgow

Nicholas W Morrell

Wei Li

Paul D Upton

Ludovic Vallier

Andrew H Baker

Margaret R MacLean

Mark Ormiston

Amer Rana

Andrew Baker

Margaret Maclean

The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10), or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.

Therapeutic use of bone morphogenetic proteins

This invention relates to the use of late out-growth endothelial progenitor cells (L-EPCs) as a cellular substrate for the generation of Induced pluripotent stem cells (iPSCs). This may be useful in the production of patient-specific tissues for disease modelling, drug and toxicology screening, tissue replacement and delivery of gene therapy.

Cellular substrate for nuclear reprogramming

The present invention provides a method of treating or preventing pulmonary arterial hypertension in a subject in need thereof by administering to the subject an inhibitor of miR-145 expression or activity. Pharmaceutical compositions and kits comprising miR-145 inhibitors for treating pulmonary arterial hypertension are also disclosed.

Methods of modulating MicroRNAs in the treatment of pulmonary arterial hypertension

Growing community of inventors

Cambridge, United Kingdom

Nicholas W Morrell